DMK Pharmaceuticals Corp (DMKPQ) Stock Price, Trades & News

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	53.2
	9-Day RSI	32.29
	14-Day RSI	32.41
	12-1 Month Momentum %	900

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History
	FCF Margin %	-261.52
	OCF Margin %	-259.01

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	EV-to-Forward-EBIT	-0.13
	EV-to-Forward-Revenue	0.4

GF Value™

DMKPQ

Warning Signs

Warning! GuruFocus detected issues with DMKPQ. Try a 7-Day Free Trial to check it out.

DMK Pharmaceuticals Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

DMK Pharmaceuticals Corp Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings results for 2026	2026-11-16	In 141 days
Second quarter earnings conference call for 2026	2026-08-14	In 47 days
Second quarter earnings results for 2026	2026-08-14	In 47 days
First quarter earnings conference call for 2026	2026-05-22	0.00 (+0.00%)
First quarter earnings results for 2026	2026-05-22	0.00 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-04-13 17:00	0.00 (+0.00%)
Annual report for 2025	2026-04-13	0.00 (+0.00%)
Fourth quarter earnings results for 2025	2026-04-13	0.00 (+0.00%)
Annual report for 2025	2026-03-16	0.00 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-23 17:00	0.00 (+0.00%)

Show

Entries

Guru Commentaries on OTCPK:DMKPQ

No articles.

Press Release

	Subject	Date
	Thinking about buying stock in Aravive, Oncolytics Biotech, Galecto, Adamis Pharmaceuticals, or Cambium Networks?	2023-08-03
	Thinking about buying stock in Tupperware Brands, Archer Aviation, Apellis Pharmaceuticals, Adamis Pharmaceuticals, or ABVC BioPharma?	2023-08-02
	Thinking about buying stock in MicroStrategy, Adamis Pharmaceuticals, Lulu's Fashion Lounge Holdings, Lucid Group, or Virgin Galactic?	2023-06-26
	SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Adamis Pharmaceuticals Corp. - ADMP	2023-03-01
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, BTE, ADMP, VBLT	2023-02-28
	ADMP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adamis Pharmaceuticals Corporation Is Fair to Shareholders	2023-02-28
	Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?	2022-01-10
	Thinking about buying stock in Progenity, Atea Pharmaceuticals, Peabody Energy, Adamis Pharmaceuticals, or Ion Geophysical?	2021-10-19
	Thinking about buying stock in Bio-Path Holdings, AzurRx BioPharma, Adamis Pharmaceuticals, indie Semiconductor, or Orphazyme?	2021-08-24
	Adamis Announces Results of 2021 Annual Meeting of Stockholders	2021-07-19

10/Page

Articles on DMK Pharmaceuticals Corp

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.